These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20017577)

  • 41. Using toxicological evidence from QSAR models in practice.
    Benfenati E; Pardoe S; Martin T; Gonella Diaza R; Lombardo A; Manganaro A; Gissi A
    ALTEX; 2013; 30(1):19-40. PubMed ID: 23338804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro toxicity: mechanisms, alternatives and validation - a report from the 19th annual scientific meeting of the Scandinavian Society for Cell Toxicology.
    Forsby A
    Altern Lab Anim; 2002; 30(3):307-8. PubMed ID: 12106008
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The current status and future applicability of quantitative structure-activity relationships (QSARs) in predicting toxicity.
    Cronin MT
    Altern Lab Anim; 2002 Dec; 30 Suppl 2():81-4. PubMed ID: 12513655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validation of Alternative In Vitro Methods to Animal Testing: Concepts, Challenges, Processes and Tools.
    Griesinger C; Desprez B; Coecke S; Casey W; Zuang V
    Adv Exp Med Biol; 2016; 856():65-132. PubMed ID: 27671720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Food for thought ... on in silico methods in toxicology.
    Hartung T; Hoffmann S
    ALTEX; 2009; 26(3):155-66. PubMed ID: 19907903
    [No Abstract]   [Full Text] [Related]  

  • 46. SEURAT: Safety Evaluation Ultimately Replacing Animal Testing--recommendations for future research in the field of predictive toxicology.
    Daston G; Knight DJ; Schwarz M; Gocht T; Thomas RS; Mahony C; Whelan M
    Arch Toxicol; 2015 Jan; 89(1):15-23. PubMed ID: 25433540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Commentary on ''Toxicity testing in the 21st century: a vision and a strategy''.
    Phalen RF
    Hum Exp Toxicol; 2010 Jan; 29(1):11-4. PubMed ID: 20061462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Commentary on ''Toxicity testing in the 21st century: a vision and a strategy''.
    Schwartz SL
    Hum Exp Toxicol; 2010 Jan; 29(1):15-9. PubMed ID: 20061463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico approaches to explore toxicity end points: issues and concerns for estimating human health effects.
    Matthews EJ; Contrera JF
    Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):125-34. PubMed ID: 17269899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and validation of an ontology-driven animal-free testing strategy for developmental neurotoxicity testing.
    Hessel EVS; Staal YCM; Piersma AH
    Toxicol Appl Pharmacol; 2018 Sep; 354():136-152. PubMed ID: 29544899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrated Approaches to Testing and Assessment.
    Casati S
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():51-55. PubMed ID: 29604238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. QSAR, Read-across and REACH.
    Barratt MD
    Altern Lab Anim; 2003 Nov; 31(5):463-5. PubMed ID: 15598173
    [No Abstract]   [Full Text] [Related]  

  • 53. Assuring safety without animal testing: Unilever's ongoing research programme to deliver novel ways to assure consumer safety.
    Westmoreland C; Carmichael P; Dent M; Fentem J; MacKay C; Maxwell G; Pease C; Reynolds F
    ALTEX; 2010; 27(3):61-5. PubMed ID: 21113564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative test methods in inhalation toxicology: challenges and opportunities.
    Costa DL
    Exp Toxicol Pathol; 2008 Jun; 60(2-3):105-9. PubMed ID: 18486462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrating (Q)SAR models, expert systems and read-across approaches for the prediction of developmental toxicity.
    Hewitt M; Ellison CM; Enoch SJ; Madden JC; Cronin MT
    Reprod Toxicol; 2010 Aug; 30(1):147-60. PubMed ID: 20006701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uncertainty of testing methods--what do we (want to) know?
    Paparella M; Daneshian M; Hornek-Gausterer R; Kinzl M; Mauritz I; Mühlegger S
    ALTEX; 2013; 30(2):131-44. PubMed ID: 23665803
    [TBL] [Abstract][Full Text] [Related]  

  • 57. t⁴ workshop report. Nanotoxicology: "the end of the beginning" - signs on the roadmap to a strategy for assuring the safe application and use of nanomaterials.
    Silbergeld EK; Contreras EQ; Hartung T; Hirsch C; Hogberg H; Jachak AC; Jordan W; Landsiedel R; Morris J; Patri A; Pounds JG; de Vizcaya Ruiz A; Shvedova A; Tanguay R; Tatarazako N; van Vliet E; Walker NJ; Wiesner M; Wilcox N; Zurlo J
    ALTEX; 2011; 28(3):236-41. PubMed ID: 21993959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing.
    Gubbels-van Hal WM; Blaauboer BJ; Barentsen HM; Hoitink MA; Meerts IA; van der Hoeven JC
    Regul Toxicol Pharmacol; 2005 Aug; 42(3):284-95. PubMed ID: 15979772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human pharmaceuticals in the aquatic environment: a review of recent toxicological studies and considerations for toxicity testing.
    Brausch JM; Connors KA; Brooks BW; Rand GM
    Rev Environ Contam Toxicol; 2012; 218():1-99. PubMed ID: 22488604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In silico toxicology in drug discovery - concepts based on three-dimensional models.
    Vedani A; Smiesko M
    Altern Lab Anim; 2009 Nov; 37(5):477-96. PubMed ID: 20017578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.